Peptide-Conjugated Lipids

DSPE-PEG1000-TH is a PEG compound which composed of DSPE and a pH-responsive cell penetrating peptide (TH). TH is activated in an acidic environment (such as the tumor microenvironment) and can selectively carry small molecules, oligonucleotides, proteins, etc. into tumor cells.

DSPE-PEG5000-CTT2 is a PEG compound which composed of DSPE and a gelatinase inhibitor (CTT2 (CTTHWGFTLC)). CTT2 (CTTHWGFTLC) has the ability to specifically target tumors. DSPE-PEG5000-CTT2 can be used for drug delivery.

DSPE-PEG5000-GRGDS is a PEG compound which composed of DSPE and an anti-adhesion peptide (GRGDS). GRGDS can block the binding and adhesion of extracellular matrix to cell surface integrins. DSPE-PEG5000-GRGDS can be used for drug delivery.

DSPE-PEG1000-GRGDS is a PEG compound which composed of DSPE and an anti-adhesion peptide (GRGDS). GRGDS can block the binding and adhesion of extracellular matrix to cell surface integrins. DSPE-PEG1000-GRGDS can be used for drug delivery.

DSPE-PEG5000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG5000-VIP can be used for drug delivery.

DSPE-PEG2000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG2000-VIP can be used for drug delivery.

DSPE-PEG5000-pPB is a PEG compound which composed of DSPE and a cyclic oligopeptide (pPB). pPB has a strong binding affinity with PDGFRβ, which is overexpressed on activated hepatic stellate cells (HSC). DSPE-PEG5000-pPB can be used for drug delivery.

DSPE-PEG1000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.